Live
- SCDRC vested with authority to enforce orders, issue warrants, rules Delhi High Court
- RTC Driver Dies of Heart Attack While Driving Bus
- Rs 1,000 crore earmarked for venture fund to Indian space startups: Minister
- Rahul Gandhi has not improved, he's aligned with anti-national elements: Union Minister Rijiju
- AI can help improve advanced pain management, find researchers
- Haryana sees 67.90 pc polling, says Chief Electoral Officer
- Gujarat to mark 23 years of progress under Narendra Modi's leadership with 'Vikas Saptah'
- Women’s T20 WC: Too soon to say anything, medics are looking at it, says Smriti on Harmanpreet’s injury
- World Cerebral Palsy Day: Raising awareness key to build inclusive society
- Militants in Gaza fire three rockets into Israel
Pharma cos may report lower sales in Q2
Pharma companies are likely to report sales, EBITDA and PAT growth of 10.2 per cent YoY, 9.4 per cent YoY and 14.3 per cent YoY, respectively in Q2 FY17,\" Reliance Securities said in its report here. \"However, industry expects strong recovery in domestic formulations business for most companies under our
Mumbai: Domestic pharmaceutical companies are likely to report subdued sales, EBITDA and PAT figures in the second quarter of this fiscal, even as the formulations business may see a strong recovery, a report said. "We expect the pharmaceutical companies to report subdued performance on sales, EBITDA and PAT front in Q2 FY17 led by the quiet US business on lack of fresh ANDA approvals due to the pending US FDA issues.
Pharma companies are likely to report sales, EBITDA and PAT growth of 10.2 per cent YoY, 9.4 per cent YoY and 14.3 per cent YoY, respectively in Q2 FY17," Reliance Securities said in its report here. "However, industry expects strong recovery in domestic formulations business for most companies under our coverage driven by strong monsoon, while favourable y-o-y movement in non-USD currencies and new drugs approvals will drive growth in emerging markets," the report said.
It said EBITDA margins will continue to be under pressure on account of increased R&D spending and adverse product-mix. "We continue to remain positive on long-term prospects of the pharma sector and recommend being stock-specific," it added. The US remains mainstay for most companies, contributing 55-60 per cent of total exports. Measures like aggressive R&D spend and scale-up in complex ANDA filings are considered to be the key re-rating triggers, it said. However, few operational metrics have exhibited lack of momentum like critical facilities under US FDA lens, channel consolidation and slowdown in approvals.
